The Cardialen UPT therapy delivers a sequence of low-energy electrical pulses designed to restore abnormally rapid heart rates to a normal rhythm. This low-energy therapy is intended to mitigate the negative effects of current high-energy defibrillators1 by delivering a much more tolerable, less debilitating treatment for patients with heart arrhythmias
Date | Amount | Type | Investors | Valuation |
---|---|---|---|---|
10/10/18 | $17,000,000 | Series B |
Cultivation Capital HBM Healthcare Investments Qiming Venture Partners RiverVest Venture Partners | undisclosed |